BGPT: Paper Review: CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology

Explore by Goal

Quick Explanation Copied

CRISPR/Cas9 as a cancer “toolkit”

Strong, readable narrative review of CRISPR/Cas9 variants (genome editing, CRISPRi/CRISPRa) and cancer applications (models, pooled screens, diagnostics, and clinical trials), but it remains non-systematic and occasionally over-optimistic about translational translation and safety timelines.

Long Explanation

npj Precision Oncology (2019) — CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology

Paper ID: 10.1038/s41698-019-0080-7

Received 11 May 2018; Accepted 18 Jan 2019.

Primary framing (what the paper claims)

The review frames CRISPR/Cas9 as a programmable system (Cas9 + sgRNA) enabling sequence-specific genome cleavage guided by a PAM-adjacent target site, followed by NHEJ (indels) or HDR (precise edits).
It highlights CRISPRi/CRISPRa as dCas9-based transcriptional repression/activation systems for reversible gene-expression modulation.
It argues CRISPR-based functional genomics (including pooled sgRNA libraries and combinatorial knockout strategies) accelerates identification of oncogenes/suppressors, synthetic lethal interactions, and resistance mechanisms.
It reports early translational momentum via clinical trials (notably PD-1 knockout approaches in T cells and related immunotherapy concepts), while stating delivery and safety/off-target/immune-response issues remain central.

Visual synthesis from the paper’s extracted quantitative snippets

The paper includes an internal PubMed-based bibliometric breakdown and a clinical-trial count. Below plots use only the specific numeric values presented in the provided full text/extraction.

Evidence note for the plots

The subtype/topic percentages used above are explicitly reported by the paper’s PubMed searches and plotted descriptions.

Mechanistic toolkit overview (with critical boundaries)

Genome editing (Cas9)

Core logic: sgRNA directs Cas9 to a PAM-specified genomic locus; Cas9 generates a DSB and repair yields either NHEJ-driven indels or HDR-mediated precise changes.
Why it matters in cancer: This supports both loss-of-function (KO) and, in principle, precise correction/knock-in strategies for cancer-associated drivers and resistance mechanisms.
Key limitation boundary: The paper explicitly notes off-target effects and delivery/safety/immune considerations are major obstacles for clinical use.

Programmable transcriptional control (dCas9: CRISPRi/a)

The review describes dCas9 as catalytically inactive Cas9 that retains RNA-guided DNA binding; CRISPRi (dCas9-KRAB) blocks transcription initiation/elongation, while CRISPRa (activator fusions like VP64/VPR) increases target transcription.
It claims CRISPRi/CRISPRa can be inducible/reversible and may reduce off-target effects/toxicity relative to some other approaches.
Critical note: Because this is a narrative review, comparative performance (e.g., “fewer off-target effects” or “low toxicity”) is not quantified across contexts within the excerpt; readers should treat it as a directional statement rather than a metrology-grade conclusion.

Cancer application map (visual concept graph)

The map is a structural summary of the review’s sections: genome editing and dCas9 derivatives enable models, pooled functional screens, and (through Cas-family collateral/trans-cleavage concepts) diagnosis-like assays, and the review describes clinical trial directions.

Clinical translation section: what is explicitly listed

Trial counts and target focus (paper-reported)

The review states that 11 clinical trials are underway testing CRISPR for cancer therapies, and that 7 of these are immunotherapies targeting the PD-1 axis.
Example trial identifiers are listed in the review’s Table 3 (e.g., NCT02793856, NCT02867345, NCT02863913, NCT02867332, NCT03081715, NCT03044743, NCT03398967, NCT03332030, NCT03166878, NCT03057912, NCT03399448).

Evidence-grade critique (skeptical review)

Strengths

Coverage of major CRISPR “modes” relevant to oncology: genome cutting/editing, dCas9-based CRISPRi/a, pooled screening logic, and translational trial directions.
Explicit acknowledgment of bottlenecks (delivery, off-target, immune response to bacterial components, vector integration risks, and ethical oversight needs).

Limitations / blind spots / where claims can overreach

Narrative review bias: The review is not presented as a systematic review with pre-registered search strategy; thus topic emphasis may track publication/activity trends rather than balanced effect-size or risk.
Translational leap risk: Preclinical editing successes do not automatically imply durable clinical efficacy; the paper itself flags this uncertainty but still uses optimistic language about “promises” and “transition to the clinic.”
Comparative claims often lack quantification in the review text: For example, statements like “CRISPRi shows less endogenous off-target effects compared to RNAi” are not shown as standardized benchmarking within the review excerpt.
Clinical trials described as “underway” without efficacy outcomes: Trial existence/phase does not establish benefit; safety and efficacy endpoints would require trial results, which the review does not provide in the excerpt.

What would disprove (falsification targets)

If CRISPR-based functional screens cannot reliably nominate causal cancer dependencies across multiple models, then the claimed acceleration of target discovery would be weakened. This can be falsified by systematic cross-model replication failures (the review’s claims are directional).
If long-term safety issues (off-target consequences, immune complications, or vector-related risks) dominate, clinical “promise” would not materialize. The paper explicitly flags these risks but does not quantify acceptable safety margins.

Paper-specific methodological note (what kind of review it is)

This manuscript functions as a narrative review of CRISPR/Cas9 mechanisms and applications in oncology, including (i) a PubMed trend query for bibliometrics, (ii) mechanistic explanations of Cas9 vs dCas9 derivatives, (iii) example application classes (models, screens, diagnostics), and (iv) clinical trial descriptions.

Quick-reference tables (from paper tables)

The review provides structured tables (Table 1–3). The excerpted content is partially garbled in the provided TEI (some cells lack context), so below I present only what is clearly legible from the provided text without inventing details.

Trial focus (as stated)	Target site	Phase	Editing strategy (as stated)	NCT ID
Advanced esophageal cancer	PD-1	Phase II	PD-1 knockout	NCT03081715
Castration resistant prostate cancer	PD-1	Phase I	PD-1 knockout	NCT02867345
Muscle-invasive bladder cancer	PD-1	Phase I	PD-1 knockout	NCT02863913
Metastatic non-small cell lung cancer	PD-1	Phase I	PD-1 knockout	NCT02793856
EBV associated malignancies	PD-1	Phase I	PD-1 knockout	NCT03044743
Metastatic renal cell carcinoma	PD-1	Phase I	PD-1 knockout	NCT02867332
Relapsed/refractory leukemia & lymphoma	CD19 (plus dual targets)	Phase I	Edit CD19 and CD20 or CD22	NCT03398967
Tumor of the central nervous system	NF1	-	Fix NF1 mutation allele	NCT03332030
Multiple myeloma	TCR	-	TCR and PD-1 knockout	NCT03399448
CD19+ leukemia & lymphoma	TCR	Phase I	TCR and B2M	NCT03166878
Human papillomavirus-related neoplasm	HPV16-E6/E7	Phase I	HPV16-E6/E7 or HPV18 E6/E7 knockout	NCT03057912

The table rows are transcribed from the provided Table 3 snippet in the paper text.

Author conflict-of-interest statement

The paper states: “Competing interests: The authors declare no competing interests.”

Explore author-specific BGPT reviews

Feedback:

Updated: April 08, 2026